

IPR & Innovation

1. [Indian innovation: Why we need to look beyond Silicon Valley](#) – Mint
2. [Return of the innovative](#) – Economic Times
3. [India rejects Lee Pharma's compulsory licence plea](#) – Economic Times

Others

1. [India, EU working to end trade huff over generic drugs](#) – MoneyControl.com
Same appeared in: [Financial Express](#), [Times of India](#), [ET HealthWorld](#)
 2. [Healthcare and IT join hands for a better future](#) – ET Health world
 3. [Finding a way through the TPP maze](#) – Business Standard
-

IPR & Innovation

1. [Indian innovation: Why we need to look beyond Silicon Valley](#) - Mint
N.R. Narayana Murthy, in his characteristic honesty, asked a pertinent question recently. Had it been a couple of decades ago, I would have been one of the graduating students listening to him at the Indian Institute of Science (IISc), my alma mater. To paraphrase him: "Why has there been no earth-shaking invention or technology from India over the last 60 years?" This is made more intriguing by the fact that Indian students, in general, and those at the Indian Institutes of Technology and IISc, in particular, are as bright, if not brighter than, the students at any top university in the US. Murthy's claim is that we have lost the "magic of the 60s" and we have to recreate it.
2. [Return of the innovative](#) – Economic Times
We are at a profound moment in India's history. We have a young and energetic workforce, a robust macroeconomy and a strong leadership at the Centre. This is our chance to power India forward. A key aspect for achieving sustainable economic growth and providing jobs to our youth is to promote innovation and entrepreneurship. We need to do more to enable our young people to think creatively, create innovative solutions, and take them to market and achieve global scale. to the innovative thinking that Indians bring to play while solving problems.
3. [India rejects Lee Pharma's compulsory licence plea](#) – Economic Times
India has decided against giving the compulsory licence for Anglo-Swedish drugmaker AstraZeneca's key antidiabetes compound Saxagliptin sought by Hyderabad-based Lee Pharma. The Controller of Patents office rejected the application on the grounds that substitutes to the drug are readily available in the market and Lee Pharma's claim that requirements of public with respect to the patented invention are not being satisfied has not been proven.

Others

1. [India, EU working to end trade huff over generic drugs](#) – MoneyControl.com
India and the European Union are taking steps to end a trade row sparked by an EU ban on Indian pharmaceutical products that New Delhi responded to by cancelling talks on a free trade accord with its largest trading partner, officials said. Indian Prime Minister Narendra Modi's office wrote to the E.U. Trade Commissioner to intervene when the ban on around 700 pharmaceutical products was formalised in May, two government sources in New Delhi said. There was no response, so the government cancelled an Aug. 28 meeting to discuss restarting talks on the free trade accord that stalled in 2012, the sources said.

2. [Healthcare and IT join hands for a better future](#) – ET Health world

Technology is at the heart of every sector that the world operates in and healthcare is not far behind in the trend. There is a huge uptake of big data and analytics in the industry. Electronic Health Record (HER) replacement has already begun, with 50% of health systems projected to be on second-generation technology by 2020. Diagnostic and other health applications are also growing with increasing use of medical images and studies with larger image sizes. Adoption of clinical next generation sequencing (NGS) applications will drive the re-evaluation of access, privacy, and data retention policies. Additional unstructured contextual content such as video, audio, and text are being stored in medical records today.

3. [Finding a way through the TPP maze](#) – Business Standard

The failure of the 12 negotiating countries of the Trans-Pacific Partnership (TPP) to meaningfully conclude an agreement in the last week of July at Maui, Hawaii, has led analysts across the world to declare the deal dead. For sure, the possibility of the deal going through and getting ratified by 2016 seems remote. A close look at what happened at the TPP meeting in Hawaii brings out the close similarity it has to what has been happening with the Doha Development Agenda of the World Trade Organization (WTO) for many years now. And like the WTO's Doha Round, TPP is also not dead, but provides several pointers to negotiators of other mega trade agreements such as the Regional Comprehensive Economic Partnership, which involves 16 countries.